Use of rasburicase in a pregnant woman with acute lymphoblastic leukaemia and imminent tumour lysis syndrome

Ann Hematol. 2014 Mar;93(3):531-2. doi: 10.1007/s00277-013-1836-8. Epub 2013 Jul 3.

Authors

Jan Moritz Middeke¹, Normi Bruck, Stefani Parmentier, Martin Bornhäuser, Johannes Schetelig

Affiliation

¹ Medizinische Klinik und Poliklinik I, University Hospital Dresden, Dresden, Germany, [email protected].

PMID: 23820942
DOI: 10.1007/s00277-013-1836-8

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Cesarean Section
Fatal Outcome
Female
Humans
Hyperuricemia / etiology
Hyperuricemia / prevention & control
Live Birth
Postpartum Period
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / physiopathology*
Pregnancy
Pregnancy Complications, Neoplastic / physiopathology*
Pregnancy Trimester, Third
Recombinant Proteins / therapeutic use
Risk
Tumor Lysis Syndrome / epidemiology
Tumor Lysis Syndrome / etiology
Tumor Lysis Syndrome / physiopathology
Tumor Lysis Syndrome / prevention & control*
Urate Oxidase / therapeutic use*
Uricosuric Agents / therapeutic use*

Substances

Recombinant Proteins
Uricosuric Agents
rasburicase
Urate Oxidase